Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Notes shall not be offered or sold in India
Stable profits, low leverage to keep credit profiles comfortable
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
